Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Phosphate Therapeutics, co-owned and resourced by Shield Therapeutics, acquires licence to and €10.5m funding for Phase 2-ready phosphate binder for treatment of hyperphosphataemia

5 Mar 2012

Shield Therapeutics (Shield), the independent specialty mineral-medicines pharmaceutical company, today notes that Phosphate Therapeutics, a company co-owned and resourced by Shield Therapeutics and its shareholders, has signed an exclusive agreement with the Medical Research Council (MRC) to acquire the global rights to PT20, a novel Phase 2 ready phosphate binder for the treatment of hyperphosphataemia. The PT20 programme was supported by funding from the MRC’s Development Gap Fund. The funding and deal was negotiated by MRC Technology. At the same time funding of up to €10.5m has been secured from Inventages Venture Capital (“Inventages

Back to news